Skip to main content

FDA in 2021: A Look Ahead

Mintz & ML Strategies

Feb
18
2021

Date: February 18, 2021

Time: 12:00PM - 1:00PM

Location: Webinar

The U.S. Food and Drug Administration (FDA) had an extraordinarily busy 2020, and things do not appear to be slowing down anytime soon. With its emergency use authorization (EUA) statute being tested in a pandemic for the first time, the agency has had a lot to learn while also maintaining its routine activities of pushing forward modernized policies for software in/as a medical device, approving innovative new therapeutic products (53 in 2020), trying to inspect manufacturing facilities to ensure product quality, and grappling with thorny regulatory issues that have been building for some time like how strictly to enforce conditions that attach to products marketed after receiving accelerated approval. Join Mintz attorney Joanne Hawana and Aaron Josephson and Anthony DeMaio from ML Strategies for a fireside discussion to explore policy activities that will likely have the greatest impact on stakeholders in 2021, and how the new Administration may impact the FDA in the year ahead and beyond.

Program topics will include:

  • What more can FDA do to speed the nation’s recovery from COVID-19? How can it also ensure that medical products sold under an EUA do not negatively affect the agency’s credibility?
  • Who is the likely FDA Commissioner nominee and what can we expect from him/her? 
  • Will FDA’s new Digital Health Center of Excellence advance digital health for drugs and devices and what are the possible impacts on regulated entities?
  • Will FDA or Congress act on patient safety issues like LDT oversight, device servicing, and regenerative medicine?
  • What do we expect to see out of the 2022 user fee reauthorization negotiations?

Register for Event

Speakers

Professional Cropped DeMaio Anthony Mintz

Anthony M. DeMaio

Moderator

Anthony M. DeMaio, Director of Government Relations of ML Strategies, draws on over a decade of experience in government affairs and communications - working with members of the Massachusetts congressional delegation - to lobby on behalf of a variety of clients and assist them with congressional investigations and media messaging.
Aaron L. Josephson is a Senior Director of ML Strategies who advises clients on health care policy issues related to medical devices and pharmaceuticals. Earlier, he was with the US Food and Drug Administration, including as a senior policy advisor in the Center for Devices and Radiological Health.

Speaker